Drug intelligence / Profile preview

[123I]beta-CIT

Development stage: Phase 2
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

A radioiodinated cocaine analog used as a radiotracer in SPECT imaging to visualize dopamine transporters (DAT) and serotonin transporters (SERT) in the brain. It has a physical half-life of approximately 13 hours and requires imaging around 20-30 hours after injection to achieve stable levels of striatal radioactivity. It's primarily used in research and clinical settings for evaluating patients with movement disorders like Parkinson's disease.

Brand names: DOPASCAN
Other names: 2beta-carbomethoxy-3beta-[4-iodophenyl]tropane

Targets

SERT (Sodium-dependent serotonin transporter)DAT (Dopamine plasma membrane transport protein)

Beyond the preview

Go deeper on [123I]beta-CIT.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on [123I]beta-CIT.

Explore the full profile